SEC Form 4 · accession 0001618835-18-000074
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kelly Culwell
Officer — Chief Medical Officer
Period of report
Jul 31, 2018
Accepted (ET)
Aug 2, 2018 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common StockF1 | $2.10 | Jul 31, 2018 | A | 98,800 | A | — | Jul 31, 2028 | Common Stock | 98,800 | 98,800 | D |
Explanation of responses
- F1The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from July 31, 2018.